Minerva Neurosciences, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. Minerva is a clinical-stage biopharmaceutical company developing CNS treatments; it had no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Collaborative revenue | $41.2 million | None | $41.2 million | None |
| R&D expense | $5.8 million | $8.3 million | $13.8 million | $19.9 million |
| G&A expense | $5.9 million | $4.6 million | $10.1 million | $9.3 million |
| Net income (loss) | $29.5 million | $(12.5) million | $17.4 million | $(28.3) million |
| Net income (loss) per diluted share | $0.73 | $(0.32) | $0.43 | $(0.73) |
- The $41.2 million collaborative revenue was a one-time recognition of previously deferred amounts following the Janssen agreement opt-out: a prior $30 million payment and $11.2 million of previously accrued expenses forgiven. It was not product-sales revenue or a new cash receipt for the quarter; the company reported no future performance obligations under that agreement.
- Six-month operating cash use was $16.8 million, versus $19.7 million in 2019. Cash, cash equivalents and restricted cash rose to $32.4 million from $21.5 million at year-end; marketable securities were $3.0 million. Combined cash and securities totaled $35.3 million.
- At June 30, current assets were $35.9 million and current liabilities $7.4 million. Total liabilities were $9.2 million, including lease liabilities and deferred taxes; no outstanding term loan is reported (the former term loans were repaid in 2018). Total stockholders’ equity was $56.9 million.
- There is no meaningful recurring operating margin to assess: reported profit chiefly reflects the Janssen-related one-time revenue. Investment income fell to $25,000 in Q2 from $434,000 a year earlier, and to $155,000 for the six-month period from $925,000.
Material changes, outlook and risks
- Roluperidone Phase 3: The trial did not meet its primary endpoint or key secondary endpoint at Week 12. Neither dose separated statistically from placebo on the primary measure after multiplicity adjustment. The company cited a larger-than-expected placebo effect as a possible explanation, is conducting further analyses and plans to seek an FDA meeting on potential next steps. The drug was generally well tolerated; treatment-emergent adverse events occurred in 37% of the 64 mg group, 42% of the 32 mg group and 33% of placebo patients.
- Janssen/seltorexant: Minerva opted out of the co-development agreement and resolved disputes with Janssen. It is eligible for a mid-single-digit royalty on worldwide seltorexant sales in all indications, if sales occur, and has no further development-cost obligations to Janssen. Royalty revenue is uncertain and was not reported in the period.
- R&D expense declined year over year, mainly because roluperidone trial costs were lower and the MIN-117 Phase 2b trial had concluded. G&A expense rose, principally due to stock-based compensation and severance. Management said it had significantly reduced planned spending after the roluperidone result and expects lower spending while it evaluates the data.
- Management believes available cash and securities will cover commitments for at least 12 months after issuance of the financial statements, but expects continued operating losses and negative operating cash flow and says additional capital will be needed to continue operations and fully fund later-stage development. It cautions that financing may not be available on acceptable terms; operations could otherwise be scaled back or discontinued.
- Minerva raised approximately $5.0 million net through its at-the-market offering in June, and a further approximately $2.4 million net from share sales through July 29, 2020. These financings dilute existing shareholders. COVID-19 had not materially affected operations to date, but could disrupt trials, timelines, productivity and access to capital. No material adverse legal proceeding was identified.
Important facts for investors to verify
- What the completed roluperidone data analyses show, and whether the FDA supports a viable next development path.
- Whether Minerva can sustain its reduced spending and secure additional funding beyond management’s stated 12-month runway.
- Progress, regulatory outcomes and eventual commercial prospects for Janssen’s seltorexant program; royalty receipts depend on future sales.
- The effects of continuing COVID-19 disruptions, clinical-development costs and further equity issuance on timelines, liquidity and shareholder dilution.